ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA has identified genetic variations in cardiac receptors that it believes may predict individual patient response to Gencaro, giving Gencaro the potential to be the first genetically-targeted prevention treatment for AF.
Cyborg Score Rationale
ARCA operates as a clinical-stage biotech with a focused precision medicine strategy and advanced lead candidate, but faces significant execution risk given no approved products, limited financial resources, and ongoing strategic review activities initiated in 2022. The company's ability to advance Gencaro through later-stage trials and secure commercialization remains uncertain.
Top Insights
ARCA operates as a clinical-stage biopharmaceutical company with a precision medicine approach to cardiovascular disease therapy development
Company operates with approximately 25 employees and $4 million in reported revenue
ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception
In May 2022, ARCA retained strategic advisors to evaluate merger, asset sale, or alternative transactions to maximize shareholder value, with no defined timeline or guaranteed outcome
Named Competitors
Lexeo Therapeutics — Precision medicine company focused on genetic cardiovascular diseases including cardiomyopathy
Tenaya Therapeutics — Precision medicine company developing genetically-targeted therapies for heart failure
Akcea Therapeutics — Cardiovascular precision medicine company focused on genetic lipid disorders
Videregen Biotechnology — Precision medicine company developing therapies for genetic cardiovascular diseases
Recent Developments
(May 2022) Initiated formal strategic review process to evaluate merger, sale, or other alternatives to maximize shareholder value
Open the full interactive ARCA biopharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.